These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 36567960)

  • 81. Ribonanza: deep learning of RNA structure through dual crowdsourcing.
    He S; Huang R; Townley J; Kretsch RC; Karagianes TG; Cox DBT; Blair H; Penzar D; Vyaltsev V; Aristova E; Zinkevich A; Bakulin A; Sohn H; Krstevski D; Fukui T; Tatematsu F; Uchida Y; Jang D; Lee JS; Shieh R; Ma T; Martynov E; Shugaev MV; Bukhari HST; Fujikawa K; Onodera K; Henkel C; Ron S; Romano J; Nicol JJ; Nye GP; Wu Y; Choe C; Reade W; ; Das R
    bioRxiv; 2024 Jun; ():. PubMed ID: 38464325
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Theoretical basis for stabilizing messenger RNA through secondary structure design.
    Wayment-Steele HK; Kim DS; Choe CA; Nicol JJ; Wellington-Oguri R; Watkins AM; Sperberg RAP; Huang PS; Participants E; Das R
    bioRxiv; 2021 Feb; ():. PubMed ID: 32869022
    [TBL] [Abstract][Full Text] [Related]  

  • 83. RNA secondary structure packages evaluated and improved by high-throughput experiments.
    Wayment-Steele HK; Kladwang W; Strom AI; Lee J; Treuille A; Becka A; ; Das R
    Nat Methods; 2022 Oct; 19(10):1234-1242. PubMed ID: 36192461
    [TBL] [Abstract][Full Text] [Related]  

  • 84. Crowdsourced RNA design discovers diverse, reversible, efficient, self-contained molecular switches.
    Andreasson JOL; Gotrik MR; Wu MJ; Wayment-Steele HK; Kladwang W; Portela F; Wellington-Oguri R; ; Das R; Greenleaf WJ
    Proc Natl Acad Sci U S A; 2022 May; 119(18):e2112979119. PubMed ID: 35471911
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Combinatorial optimization of mRNA structure, stability, and translation for RNA-based therapeutics.
    Leppek K; Byeon GW; Kladwang W; Wayment-Steele HK; Kerr CH; Xu AF; Kim DS; Topkar VV; Choe C; Rothschild D; Tiu GC; Wellington-Oguri R; Fujii K; Sharma E; Watkins AM; Nicol JJ; Romano J; Tunguz B; Diaz F; Cai H; Guo P; Wu J; Meng F; Shi S; Participants E; Dormitzer PR; Solórzano A; Barna M; Das R
    Nat Commun; 2022 Mar; 13(1):1536. PubMed ID: 35318324
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Principles for designing an optimal mRNA lipid nanoparticle vaccine.
    Kon E; Elia U; Peer D
    Curr Opin Biotechnol; 2022 Feb; 73():329-336. PubMed ID: 34715546
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Theoretical basis for stabilizing messenger RNA through secondary structure design.
    Wayment-Steele HK; Kim DS; Choe CA; Nicol JJ; Wellington-Oguri R; Watkins AM; Parra Sperberg RA; Huang PS; Participants E; Das R
    Nucleic Acids Res; 2021 Oct; 49(18):10604-10617. PubMed ID: 34520542
    [TBL] [Abstract][Full Text] [Related]  

  • 88. mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability.
    Schoenmaker L; Witzigmann D; Kulkarni JA; Verbeke R; Kersten G; Jiskoot W; Crommelin DJA
    Int J Pharm; 2021 May; 601():120586. PubMed ID: 33839230
    [TBL] [Abstract][Full Text] [Related]  

  • 89. Serum Neutralizing Activity Elicited by mRNA-1273 Vaccine.
    Wu K; Werner AP; Koch M; Choi A; Narayanan E; Stewart-Jones GBE; Colpitts T; Bennett H; Boyoglu-Barnum S; Shi W; Moliva JI; Sullivan NJ; Graham BS; Carfi A; Corbett KS; Seder RA; Edwards DK
    N Engl J Med; 2021 Apr; 384(15):1468-1470. PubMed ID: 33730471
    [No Abstract]   [Full Text] [Related]  

  • 90. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.
    Baden LR; El Sahly HM; Essink B; Kotloff K; Frey S; Novak R; Diemert D; Spector SA; Rouphael N; Creech CB; McGettigan J; Khetan S; Segall N; Solis J; Brosz A; Fierro C; Schwartz H; Neuzil K; Corey L; Gilbert P; Janes H; Follmann D; Marovich M; Mascola J; Polakowski L; Ledgerwood J; Graham BS; Bennett H; Pajon R; Knightly C; Leav B; Deng W; Zhou H; Han S; Ivarsson M; Miller J; Zaks T;
    N Engl J Med; 2021 Feb; 384(5):403-416. PubMed ID: 33378609
    [TBL] [Abstract][Full Text] [Related]  

  • 91. Addressing the Cold Reality of mRNA Vaccine Stability.
    Crommelin DJA; Anchordoquy TJ; Volkin DB; Jiskoot W; Mastrobattista E
    J Pharm Sci; 2021 Mar; 110(3):997-1001. PubMed ID: 33321139
    [TBL] [Abstract][Full Text] [Related]  

  • 92. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.
    Polack FP; Thomas SJ; Kitchin N; Absalon J; Gurtman A; Lockhart S; Perez JL; Pérez Marc G; Moreira ED; Zerbini C; Bailey R; Swanson KA; Roychoudhury S; Koury K; Li P; Kalina WV; Cooper D; Frenck RW; Hammitt LL; Türeci Ö; Nell H; Schaefer A; Ünal S; Tresnan DB; Mather S; Dormitzer PR; Şahin U; Jansen KU; Gruber WC;
    N Engl J Med; 2020 Dec; 383(27):2603-2615. PubMed ID: 33301246
    [TBL] [Abstract][Full Text] [Related]  

  • 93. A Thermostable mRNA Vaccine against COVID-19.
    Zhang NN; Li XF; Deng YQ; Zhao H; Huang YJ; Yang G; Huang WJ; Gao P; Zhou C; Zhang RR; Guo Y; Sun SH; Fan H; Zu SL; Chen Q; He Q; Cao TS; Huang XY; Qiu HY; Nie JH; Jiang Y; Yan HY; Ye Q; Zhong X; Xue XL; Zha ZY; Zhou D; Yang X; Wang YC; Ying B; Qin CF
    Cell; 2020 Sep; 182(5):1271-1283.e16. PubMed ID: 32795413
    [TBL] [Abstract][Full Text] [Related]  

  • 94. Evaluation of the mRNA-1273 Vaccine against SARS-CoV-2 in Nonhuman Primates.
    Corbett KS; Flynn B; Foulds KE; Francica JR; Boyoglu-Barnum S; Werner AP; Flach B; O'Connell S; Bock KW; Minai M; Nagata BM; Andersen H; Martinez DR; Noe AT; Douek N; Donaldson MM; Nji NN; Alvarado GS; Edwards DK; Flebbe DR; Lamb E; Doria-Rose NA; Lin BC; Louder MK; O'Dell S; Schmidt SD; Phung E; Chang LA; Yap C; Todd JM; Pessaint L; Van Ry A; Browne S; Greenhouse J; Putman-Taylor T; Strasbaugh A; Campbell TA; Cook A; Dodson A; Steingrebe K; Shi W; Zhang Y; Abiona OM; Wang L; Pegu A; Yang ES; Leung K; Zhou T; Teng IT; Widge A; Gordon I; Novik L; Gillespie RA; Loomis RJ; Moliva JI; Stewart-Jones G; Himansu S; Kong WP; Nason MC; Morabito KM; Ruckwardt TJ; Ledgerwood JE; Gaudinski MR; Kwong PD; Mascola JR; Carfi A; Lewis MG; Baric RS; McDermott A; Moore IN; Sullivan NJ; Roederer M; Seder RA; Graham BS
    N Engl J Med; 2020 Oct; 383(16):1544-1555. PubMed ID: 32722908
    [TBL] [Abstract][Full Text] [Related]  

  • 95. mRNA structure regulates protein expression through changes in functional half-life.
    Mauger DM; Cabral BJ; Presnyak V; Su SV; Reid DW; Goodman B; Link K; Khatwani N; Reynders J; Moore MJ; McFadyen IJ
    Proc Natl Acad Sci U S A; 2019 Nov; 116(48):24075-24083. PubMed ID: 31712433
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Double-Stranded RNA Sensors and Modulators in Innate Immunity.
    Hur S
    Annu Rev Immunol; 2019 Apr; 37():349-375. PubMed ID: 30673536
    [TBL] [Abstract][Full Text] [Related]  

  • 97. bpRNA: large-scale automated annotation and analysis of RNA secondary structure.
    Danaee P; Rouches M; Wiley M; Deng D; Huang L; Hendrix D
    Nucleic Acids Res; 2018 Jun; 46(11):5381-5394. PubMed ID: 29746666
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Advances in the delivery of RNA therapeutics: from concept to clinical reality.
    Kaczmarek JC; Kowalski PS; Anderson DG
    Genome Med; 2017 Jun; 9(1):60. PubMed ID: 28655327
    [TBL] [Abstract][Full Text] [Related]  

  • 99. Introduction to RNA Vaccines.
    Kramps T; Elbers K
    Methods Mol Biol; 2017; 1499():1-11. PubMed ID: 27987140
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Principles for Predicting RNA Secondary Structure Design Difficulty.
    Anderson-Lee J; Fisker E; Kosaraju V; Wu M; Kong J; Lee J; Lee M; Zada M; Treuille A; Das R;
    J Mol Biol; 2016 Feb; 428(5 Pt A):748-757. PubMed ID: 26902426
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.